At a glance
ClinicalIndex Comparison RecordN/ACompleted· 299 enrolled
Drug / intervention
Obinutuzumabdrug
Likely dose
Obinutuzumab 1000 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Interventional, Retrospective And Prospective, Multicenter, Single Arm Study Evaluating The Effectiveness And Safety Of Obinutuzumab In Patients With Previously Untreated Advanced Follicular Lymphoma
In Brief
An observational study evaluating Obinutuzumab for Follicular Lymphoma. Completed, enrolled 299 participants across 46 sites.
Detailed Summary
To evaluate the effectiveness and safety of obinutuzumab in clinical routine in 1L FL measured by the % of relapse within 24 months from start of therapy.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsFollicular Lymphoma
CountriesItaly
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartSep 2019
Primary CompletionApr 2024
TodayJul 2026
First PostedJul 26, 2019
Enrollment StartSep 2, 2019
Primary CompletionApr 22, 2024
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 6.9 years ago
Interventions
Obinutuzumabdrug
Induction phase: 1000 milligram (mg) intravenously (IV) on Day 1, 8, 15 of Cycle 1 an Day 1 of Cycles 2-6 or 2-8. Maintenance phase: 1000 mg IV every 2 months for 2 years or until disease progression (whatever occurs earlier).